<DOC>
	<DOCNO>NCT01941082</DOCNO>
	<brief_summary>This multicenter , non-randomized , open-label , single- multiple-ascending-dose study investigate safety , tolerability , pharmacokinetics pharmacodynamics RO6867461 patient wet age-related macular degeneration .</brief_summary>
	<brief_title>A Study RO6867461 Administered Single- Multiple-Ascending Doses Patients With Wet Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Adult patient , &gt; /= 50 year age Patients agerelated macular degeneration ( AMD ) Best correct visual acuity ( BCVA ) 20/40 20/400 ( Snellen equivalent , ETDRA chart ) inclusive Evidence leakage due choroidal neovascularization ( CNV ) Choroidal neovascularization ( CNV ) either eye due cause age relate macular degeneration , ocular histoplasmosis , trauma , pathologic myopia Known hypersensitivity ranibizumab , fluorescein , indocyanin green ( ICG ) ingredients formulation use , medication use Any restriction accord use ranibizumab Active intraocular inflammation ( grade trace ) study eye Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>